Short Interest in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Rises By 382.5%

Posted by Stephan Jacobs on Jul 13th, 2026

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 108,461 shares, an increase of 382.5% from the June 15th total of 22,477 shares. Based on an average daily trading volume, of 77,170 shares, the short-interest ratio is currently 1.4 days. Approximately 1.9% of the company’s shares are short sold.

Institutional Trading of iShares Genomics Immunology and Healthcare ETF

A hedge fund recently raised its position in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. raised its position in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Free Report) by 8.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,473 shares of the company’s stock after acquiring an additional 5,540 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 at the end of the most recent quarter.

iShares Genomics Immunology and Healthcare ETF Stock Down 1.8%

Shares of IDNA traded down $0.60 during trading hours on Monday, hitting $32.95. The company had a trading volume of 120,511 shares, compared to its average volume of 44,740. iShares Genomics Immunology and Healthcare ETF has a 52-week low of $20.93 and a 52-week high of $34.97. The stock’s 50 day moving average price is $30.78 and its 200 day moving average price is $29.66. The firm has a market cap of $191.11 million, a P/E ratio of 14.76 and a beta of 0.92.

About iShares Genomics Immunology and Healthcare ETF

(Get Free Report)

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.